Midwest Allergy Sinus Asthma SC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$13,882	4
2024	Research	$44,344	13
2023	Research	$36,451	14
2022	Research	$71,080	19
2021	Research	$103,441	24
2020	Research	$271,246	44
2019	Research	$697,323	81

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $903,922 154 payments
Vanda Pharmaceuticals Inc. $232,834 22 payments
Novartis Pharmaceuticals Corporation $62,349 6 payments
Regeneron Pharmaceuticals, Inc. $19,882 11 payments
AstraZeneca Pharmaceuticals LP $12,045 4 payments
AstraZeneca UK Limited $6,738 2 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized Doubleblind Placebocontrolled Study to Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis $252,215 24 payments
A Phase 3 Multicenter Longterm Extension Study Investigating the Efficacy and Safety of Abrocitinib With Or Without Topical Medications Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis $245,508 66 payments
An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $233,564 36 payments
Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $232,834 22 payments
Jak1 Dupilumab Comparator Study $127,790 18 payments
A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $58,309 3 payments
A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 to 18 Years of Age With Moderatetosevere Atopic Dermatitis $44,845 10 payments
PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long-acting B2 Agonist and Chronic Oral Corticosteroid Therapy $12,045 4 payments
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, 6 Years to 12 Years of Age, With Severe Atopic Dermatitis $11,382 8 payments
A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis $8,500 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.